New targeted therapies in the treatment of patients with metastatic melanoma

Mackiewicz, Jacek; Kwinta, Łukasz

doi:10.5114/wo.2010.974

Cited by 8 publications

(13 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Higher levels of VEGF in the serum occur in patients with an advanced neoplastic process and are indicative of a negative prognosis and shorter periods of remission and, according to several authors' contention, they can have a certain prognostic value (Ugurel et al, 2001;Ascierto et al, 2004;Mackiewicz and Kwinta, 2010).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Vascular Endothelial Growth Factor (VEGF) levels in the blood serum of dogs with malignant neoplasms of the oral cavity

Sobczyńska-Rak

Polkowska

Silmanowicz

2014

Acta Veterinaria Hungarica

View full text Add to dashboard Cite

Angiogenesis plays an essential role in the development of a neoplastic tumour by conditioning both its growth and the formation of metastases. The induction of blood vessel growth occurs under the influence of proangiogenic factors, among which Vascular Endothelial Growth Factor (VEGF) seems to be the most important. The aim of this research was to study the level of VEGF measured by ELISA in the serum of dogs with neoplasms of the oral cavity. The study material comprised samples of neoplastic tissue from 17 operated dogs and the serum of the examined animals as well as of dogs from the control group. The tissue samples were taken from dogs of different breeds, aged 6–14 years. The tumour type was determined in accordance with the applicable WHO classification. Blood samples taken from sick dogs and from animals of the control group were centrifuged, and immunoenzymatic labelling of VEGF was performed in the obtained serum using ELISA and R&D system reagents (Quantikine Canine VEGF). All stages of VEGF labelling were performed according to the recommendation of the test manufacturer. The median of VEGF in the serum of the dogs with neoplasms of the oral cavity was 40.64 pg/mL. The lowest value of 14.26 pg/mL was observed in the case of fibrosarcoma, and the highest value of 99.19 pg/mL in the case of squamous cell carcinoma. The VEGF median in the control group amounted to 11.14 pg/mL whereas the VEGF value in the groups of animals diagnosed with benign tumours ranged between 2.30 and 19.74 pg/mL. Elevated VEGF in the blood serum, in comparison with the benign tumour group and the control group, was observed in all examined neoplasms of the oral cavity. It was suggested that overexpression of VEGF can have a prognostic value and is useful in the early detection of neoplasms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Antiangiogenic therapies with the use of monoclonal antibodies against VEGF or substances blocking its receptors seem to be promising, and clinical research in this direction is currently carried out on a large scale globally (Dvorak, 2002;Volk et al, 2008;Szala, 2009;Mackiewicz and Kwinta, 2010).…”

Section: Discussionmentioning

confidence: 99%

Elevated Vascular Endothelial Growth Factor (VEGF) levels in the blood serum of dogs with malignant neoplasms of the oral cavity

Sobczyńska-Rak

Polkowska

Silmanowicz

2014

Acta Veterinaria Hungarica

View full text Add to dashboard Cite

show abstract

“…14; 2 (59)(60)(61)(62)(63)(64)(65)(66)(67)(68)(69)(70)(71) • synteza i wydzielanie czynników immunosupresyjnych, takich jak IL-10, TGF-β, PGE 2 , blokujących odpowiedź immunologiczną [11,12]; • prowadząca do apoptozy limfocytów T ekspresja TRIAL (TNF related apoptosis inducing ligand) na komórkach nowotworu [13] oraz • przewlekła stymulacja swoistych komórek T prowadząca do ich klonalnego wyczerpania (clonal exhaustion) lub śmierci (activation induced cell death -AICD) [14]. Jeżeli nowotwór ominie układ nadzoru immunologicznego, to może przejść do kolejnej podklinicznej fazy, tzw.…”

Section: Immunologiczna Odpowiedź Przeciwnowotworowaunclassified

“…Cząsteczka CTLA-4, która ulega nadekspresji na aktywowanych limfocytach T i limfocytach T-supresorowych, hamuje dalszą aktywację swoistych limfocytów T CD4+ i CD8+ poprzez interakcję z komórkami DC lub bezpośrednio w wyniku kontaktu limfocytów supresorowych z efektorowymi. Przeciwciało anty-CTLA4 poprzez blokowanie interakcji CTLA-4 z CD80/86 wyłącza ten mechanizm supresji immunologicznej i umoż-liwia ciągłe, niepohamowane stymulowanie limfocytów T przez komórki DC [63]. Dwa ludzkie przeciwciała monoklonalne IgG przeciwko CTLA-4 -ipilimumab oraz tremelimumab -były testowane w wielu badaniach klinicznych u chorych na różne nowotwory.…”

Section: Nieswoista Czynna Immunoterapiaunclassified

Immunotherapy of cancer and perspectives of its development

Mackiewicz¹,

Maćkiewicz²

2010

Self Cite

View full text Add to dashboard Cite

“…The anti-CTLA4 monoclonal antibody by blocking the interaction of CTLA-4 with CD80/86 switches off the mechanism of immune suppression and enables continous, unrestrained stimulation of T-cells by DC (J. Mackiewicz & Kwinta, 2010). Two IgG monoclonal antibodies directed against CTLA-4 -ipilimumab and tremelimumab have been tested in number of clinical trials in patients with melanoma.…”

Section: Active Non-specific Immunotherapymentioning

confidence: 99%